Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

被引：0
|
作者：
Kilickap, S. [1 ]
Sezer, A. [2 ]
Gumus, M. [3 ]
Bondarenko, I. [4 ]
Ozguroglu, M. [5 ]
Gogishvili, M. [6 ]
He, X. [7 ]
Gullo, G. [7 ]
Rietschel, P. [7 ]
Quek, R. G. [7 ]
机构：
[1] Istinye Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[4] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[5] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; patient-reported outcomes; cemiplimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-12
引用
收藏
页码：S125 / S126
页数：2
相关论文
共 50 条
  • [1] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [2] EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S931
  • [3] Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
    Gumus, M.
    Kilickap, S.
    Sezer, A.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S321
  • [4] Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3
    Baramidze, A.
    Gessner, C.
    Gogishvili, M.
    Sezer, A.
    Makharadze, T.
    Kilickap, S.
    Gumus, M.
    Li, Y.
    Li, S.
    Salvati, M.
    Pouliot, J. -F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S316 - S317
  • [5] Predictive Utility of Patient-Reported Outcomes for Survival in 1st-Line Treated Patients with a NSCLC in EMPOWER-Lung 1 and 3
    Gandara, D. R.
    Gogishvili, M.
    Sezer, A.
    Makharadze, T.
    Guemues, M.
    McIntyre, D. A.
    He, X.
    Yan, E.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S117 - S117
  • [6] EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S932
  • [7] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
    Baramidze, Ana
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Giorgadze, Davit
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    McIntyre, Debra A. G.
    Perez, Javier
    Kaul, Manika
    Quek, Ruben G. W.
    Seebach, Frank
    Rietschel, Petra
    Pouliot, Jean-Francois
    LUNG CANCER, 2024, 193
  • [8] First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Schenker, Michael
    Audigier-Valette, Clarisse
    Zurawski, Bogdan
    Linardou, Helena
    Otterson, Gregory A.
    Salman, Pamela
    Nishio, Makoto
    Jimenez, Emmanuel de la Mora
    Lesniewski-Kmak, Krysztof
    Albert, Istvan
    Ahmed, Samreen
    Syrigos, Konstantinos
    Penrod, John R.
    Yuan, Yong
    Blum, Steven, I
    Nathan, Faith E.
    Sun, Xiaowu
    Moreno-Koehler, Alejandro
    Taylor, Fiona
    O'Byrne, Kenneth John
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 665 - 676
  • [9] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [10] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
    Makharadze, Tamta
    Quek, Ruben G. W.
    Melkadze, Tamar
    Gogishvili, Miranda
    Ivanescu, Cristina
    Giorgadze, Davit
    Dvorkin, Mikhail
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Gessner, Christian
    Moreno-Jaime, Brizio
    Passalacqua, Rodolfo
    Konidaris, Gerasimos
    Rietschel, Petra
    Gullo, Giuseppe
    CANCER, 2023, 129 (14) : 2256 - 2265
12345